ResearcherFox Chase Cancer CenterNo recent work listed
Egor Bobrov
Matched on OpenAlex author ID A5071462114. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2016: 1 paper · 2017: 1 paper
Papers 2
- Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Co-author DOI 10.18632/oncotarget.12642↗
- Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0149↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Natalya Beglyarova · 2 shared papers, 2016–2017 · strength 0.11
- Paper Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer mode… DOI 10.18632/oncotarget.12642↗
- Paper Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target i… DOI 10.1158/1078-0432.ccr-16-0149↗
- Igor A. Astsaturov · 2 shared papers, 2016–2017 · strength 0.11
- Paper Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer mode… DOI 10.18632/oncotarget.12642↗
- Paper Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target i… DOI 10.1158/1078-0432.ccr-16-0149↗
- Erica A. Golemis · 2 shared papers, 2016–2017 · strength 0.11
- Paper Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer mode… DOI 10.18632/oncotarget.12642↗
- Paper Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target i… DOI 10.1158/1078-0432.ccr-16-0149↗
- Diana Behrens · 1 shared paper, 2016 · strength 0.04
- John Parker Hoffman · 1 shared paper, 2016 · strength 0.04
- Louis M. Weiner · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.